Investors bought shares of CVS Health Corp (NYSE:CVS) on weakness during trading hours on Thursday. $117.15 million flowed into the stock on the tick-up and $78.96 million flowed out of the stock on the tick-down, for a money net flow of $38.19 million into the stock. Of all equities tracked, CVS Health had the 19th highest net in-flow for the day. CVS Health traded down ($0.43) for the day and closed at $75.09
Several equities analysts have recently commented on the company. Royal Bank of Canada reiterated a “buy” rating and set a $90.00 target price on shares of CVS Health in a research note on Wednesday, August 8th. Leerink Swann set a $80.00 target price on CVS Health and gave the company an “outperform” rating in a research note on Thursday, August 9th. ValuEngine upgraded CVS Health from a “strong sell” rating to a “sell” rating in a research note on Monday, September 10th. Argus increased their target price on CVS Health to $100.00 and gave the company a “buy” rating in a research note on Tuesday, November 13th. Finally, Wolfe Research assumed coverage on CVS Health in a research note on Thursday, October 25th. They set a “peer perform” rating for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $90.04.
The company has a market capitalization of $76.94 billion, a PE ratio of 12.73, a price-to-earnings-growth ratio of 1.01 and a beta of 0.98. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.44 and a quick ratio of 1.94.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Investors of record on Wednesday, October 24th were paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 2.66%. The ex-dividend date was Tuesday, October 23rd. CVS Health’s dividend payout ratio (DPR) is presently 33.90%.
In related news, EVP Eva C. Boratto sold 13,311 shares of the firm’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the transaction, the executive vice president now directly owns 55,162 shares in the company, valued at $4,256,299.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Hourican sold 8,564 shares of the firm’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $75.00, for a total value of $642,300.00. Following the transaction, the executive vice president now owns 12,135 shares in the company, valued at $910,125. The disclosure for this sale can be found here. Insiders have sold 57,638 shares of company stock worth $4,558,875 over the last 90 days. 0.53% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in CVS. Hayek Kallen Investment Management lifted its stake in CVS Health by 5.0% in the third quarter. Hayek Kallen Investment Management now owns 13,567 shares of the pharmacy operator’s stock valued at $844,000 after buying an additional 641 shares during the last quarter. Trust Co. of Toledo NA OH lifted its stake in CVS Health by 3.5% in the third quarter. Trust Co. of Toledo NA OH now owns 19,653 shares of the pharmacy operator’s stock valued at $1,548,000 after buying an additional 661 shares during the last quarter. Intersect Capital LLC lifted its stake in CVS Health by 6.1% in the third quarter. Intersect Capital LLC now owns 11,622 shares of the pharmacy operator’s stock valued at $915,000 after buying an additional 665 shares during the last quarter. Assetmark Inc. lifted its stake in CVS Health by 14.3% in the third quarter. Assetmark Inc. now owns 5,319 shares of the pharmacy operator’s stock valued at $419,000 after buying an additional 665 shares during the last quarter. Finally, Kiley Juergens Wealth Management LLC lifted its stake in CVS Health by 41.5% in the third quarter. Kiley Juergens Wealth Management LLC now owns 2,270 shares of the pharmacy operator’s stock valued at $178,000 after buying an additional 666 shares during the last quarter. Hedge funds and other institutional investors own 83.03% of the company’s stock.
WARNING: “Investors Buy CVS Health (CVS) on Weakness” was published by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.wkrb13.com/2018/11/22/investors-buy-cvs-health-cvs-on-weakness.html.
About CVS Health (NYSE:CVS)
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Read More: NASDAQ
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.